Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.1K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.1K
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

912
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
912

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outcomes of allogeneic ocular surface stem cell transplantation.

Frontiers in ophthalmology·2026
Same author

Using Lotilaner Ophthalmic Solution, 0.25% to Treat <i>Demodex</i> Blepharitis in Patients Who Were Initially Misdiagnosed: A Case Series.

Clinical optometry·2026
Same author

Ocular Surface Toxicity of Antibody-Drug Conjugates: Pathogenesis, Diagnosis, Grading, and Treatment of Ocular Adverse Effects.

Cornea·2026
Same author

Comparing Global Operating Room Waste Generated From Cataract, Corneal, and Conjunctival Surgeries.

Cornea·2026
Same author

Regenerative Ophthalmology: A Paradigm Change.

American journal of ophthalmology·2026
Same author

Standardized Classification System for Dysphotopsia Reporting.

Ophthalmology. Glaucoma·2026

Related Experiment Video

Updated: Jan 4, 2026

Three Different Protocols of Corneal Collagen Crosslinking in Keratoconus: Conventional, Accelerated and Iontophoresis
07:29

Three Different Protocols of Corneal Collagen Crosslinking in Keratoconus: Conventional, Accelerated and Iontophoresis

Published on: November 12, 2015

20.3K

Corneal crosslinking: Current protocols and clinical approach.

Kenneth A Beckman1, Preeya K Gupta2, Marjan Farid3

  • 1Comprehensive Eyecare of Central Ohio, Westerville; Department of Ophthalmology, Ohio State University, Columbus.

Journal of Cataract and Refractive Surgery
|November 11, 2019
PubMed
Summary
This summary is machine-generated.

Corneal crosslinking (CXL) effectively halts keratoconus progression, significantly reducing the need for corneal transplantation. This procedure offers long-term safety and cost benefits compared to natural disease progression.

More Related Videos

Second Harmonic Generation Signals in Rabbit Sclera As a Tool for Evaluation of Therapeutic Tissue Cross-linking TXL for Myopia
12:25

Second Harmonic Generation Signals in Rabbit Sclera As a Tool for Evaluation of Therapeutic Tissue Cross-linking TXL for Myopia

Published on: January 6, 2018

8.2K
Scleral Cross-linking Using Riboflavin and Ultraviolet-A Radiation for Prevention of Axial Myopia in a Rabbit Model
05:56

Scleral Cross-linking Using Riboflavin and Ultraviolet-A Radiation for Prevention of Axial Myopia in a Rabbit Model

Published on: April 3, 2016

9.3K

Related Experiment Videos

Last Updated: Jan 4, 2026

Three Different Protocols of Corneal Collagen Crosslinking in Keratoconus: Conventional, Accelerated and Iontophoresis
07:29

Three Different Protocols of Corneal Collagen Crosslinking in Keratoconus: Conventional, Accelerated and Iontophoresis

Published on: November 12, 2015

20.3K
Second Harmonic Generation Signals in Rabbit Sclera As a Tool for Evaluation of Therapeutic Tissue Cross-linking TXL for Myopia
12:25

Second Harmonic Generation Signals in Rabbit Sclera As a Tool for Evaluation of Therapeutic Tissue Cross-linking TXL for Myopia

Published on: January 6, 2018

8.2K
Scleral Cross-linking Using Riboflavin and Ultraviolet-A Radiation for Prevention of Axial Myopia in a Rabbit Model
05:56

Scleral Cross-linking Using Riboflavin and Ultraviolet-A Radiation for Prevention of Axial Myopia in a Rabbit Model

Published on: April 3, 2016

9.3K

Area of Science:

  • Ophthalmology
  • Corneal Surgery
  • Medical Technology

Background:

  • Corneal ectasia, including keratoconus, is a progressive condition often requiring corneal transplantation.
  • Corneal crosslinking (CXL) is an emerging treatment aimed at stabilizing corneal ectasia.
  • The ASCRS Cornea Clinical Committee reviewed existing and novel CXL techniques.

Purpose of the Study:

  • To review the current literature on corneal crosslinking (CXL) for treating corneal ectasia.
  • To compare CXL techniques with corneal transplantation regarding efficacy, safety, risks, and costs.
  • To assess the impact of CXL on limiting disease progression and reducing transplantation rates.

Main Methods:

  • Systematic literature review of CXL procedures for corneal ectasia.
  • Analysis of data on current and investigational CXL techniques.
  • Comparative analysis of CXL versus natural disease progression and corneal transplantation.

Main Results:

  • Corneal crosslinking (CXL) effectively limits the progression of keratoconus.
  • CXL significantly reduces the long-term need for corneal transplantation.
  • CXL demonstrates substantial long-term safety and cost benefits compared to natural disease progression.

Conclusions:

  • Corneal crosslinking is a valuable treatment for corneal ectasia, preventing disease advancement.
  • CXL offers significant advantages over natural disease progression by improving long-term outcomes and reducing healthcare costs.
  • Ongoing research into CXL variations aims to further enhance its safety and effectiveness.